MX2017005668A - Nuevos compuestos de acido carboxilico utiles para inhibir la sintasa-1 de prostaglandina microsomal e2. - Google Patents
Nuevos compuestos de acido carboxilico utiles para inhibir la sintasa-1 de prostaglandina microsomal e2.Info
- Publication number
- MX2017005668A MX2017005668A MX2017005668A MX2017005668A MX2017005668A MX 2017005668 A MX2017005668 A MX 2017005668A MX 2017005668 A MX2017005668 A MX 2017005668A MX 2017005668 A MX2017005668 A MX 2017005668A MX 2017005668 A MX2017005668 A MX 2017005668A
- Authority
- MX
- Mexico
- Prior art keywords
- synthase
- carboxylic acid
- acid compounds
- compounds useful
- microsomal prostaglandin
- Prior art date
Links
- -1 carboxylic acid compounds Chemical class 0.000 title 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 title 1
- 229960002986 dinoprostone Drugs 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 230000003228 microsomal effect Effects 0.000 title 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a compuestos de fórmula 1, o sales farmacéuticamente aceptables de los mismos, donde R, X, A, E y G son como se describen en la presente, métodos para preparar los compuestos y uso de los compuestos para tratar dolor y/o inflamación (ver Fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462072140P | 2014-10-29 | 2014-10-29 | |
| PCT/US2015/056955 WO2016069374A1 (en) | 2014-10-29 | 2015-10-22 | Novel carboxylic acid compounds useful for inhibiting microsomal prostaglandin e2 synthase-1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017005668A true MX2017005668A (es) | 2017-06-26 |
| MX376894B MX376894B (es) | 2025-03-07 |
Family
ID=54365459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017005668A MX376894B (es) | 2014-10-29 | 2015-10-22 | Nuevos compuestos de acido carboxilico utiles para inhibir la sintasa-1 de prostaglandina microsomal e2. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9969714B2 (es) |
| EP (1) | EP3221304B1 (es) |
| JP (1) | JP6425809B2 (es) |
| KR (1) | KR101903304B1 (es) |
| CN (1) | CN107001319B (es) |
| AR (1) | AR102361A1 (es) |
| AU (1) | AU2015339737B2 (es) |
| BR (1) | BR112017006809B1 (es) |
| CA (1) | CA2963318C (es) |
| CL (1) | CL2017001050A1 (es) |
| EA (1) | EA031504B1 (es) |
| ES (1) | ES2744211T3 (es) |
| MX (1) | MX376894B (es) |
| NZ (1) | NZ730730A (es) |
| TW (1) | TW201627299A (es) |
| WO (1) | WO2016069374A1 (es) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3581B1 (ar) | 2014-10-29 | 2020-07-05 | Lilly Co Eli | مركبات ميثيل-بيبيريدين جديدة مفيدة لتثبيط إنزيم سينثاز -1 بروستاجلاندين e2 ميكروسومي |
| WO2020263830A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
| ES2973832T3 (es) | 2019-10-18 | 2024-06-24 | Forty Seven Inc | Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda |
| JP2022552748A (ja) | 2019-10-31 | 2022-12-19 | フォーティ セブン， インコーポレイテッド | 抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療 |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| CA3157769A1 (en) * | 2019-11-27 | 2021-06-03 | Eiji IDEUE | Cycloalkyl urea derivative |
| US11352357B2 (en) | 2019-11-27 | 2022-06-07 | Sumitomo Dainippon Pharma Co., Ltd. | Cycloalkylurea derivative |
| IL294032A (en) | 2019-12-24 | 2022-08-01 | Carna Biosciences Inc | Compounds that regulate diacylglycerol kinase |
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| IL297327B2 (en) | 2020-05-01 | 2026-01-01 | Gilead Sciences Inc | 4,2-dioxopyrimidine compounds CD73 inhibitors |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| AU2022375782B2 (en) | 2021-10-28 | 2026-02-26 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| JP7787991B2 (ja) | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| KR20240123836A (ko) | 2021-12-22 | 2024-08-14 | 길리애드 사이언시즈, 인코포레이티드 | 이카로스 아연 핑거 패밀리 분해제 및 이의 용도 |
| US12122764B2 (en) | 2021-12-22 | 2024-10-22 | Gilead Sciences, Inc. | IKAROS zinc finger family degraders and uses thereof |
| MX2024008003A (es) | 2021-12-28 | 2024-07-12 | Nippon Shinyaku Co Ltd | Compuesto de indazol y composicion farmaceutica. |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| KR20240165995A (ko) | 2022-03-24 | 2024-11-25 | 길리애드 사이언시즈, 인코포레이티드 | Trop-2 발현 암의 치료를 위한 병용요법 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| CR20240451A (es) | 2022-04-21 | 2024-12-04 | Gilead Sciences Inc | Compuestos de modulación de kras g12d |
| KR20250028371A (ko) | 2022-07-01 | 2025-02-28 | 길리애드 사이언시즈, 인코포레이티드 | Cd73 화합물 |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| AU2023409398A1 (en) | 2022-12-22 | 2025-06-05 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| AU2024252725A1 (en) | 2023-04-11 | 2025-11-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| CR20250446A (es) | 2023-04-21 | 2025-12-02 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| AU2024306338A1 (en) | 2023-06-30 | 2026-01-08 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN121620513A (zh) | 2023-07-26 | 2026-03-06 | 吉利德科学公司 | Parp7抑制剂 |
| KR20260046403A (ko) | 2023-07-26 | 2026-04-07 | 길리애드 사이언시즈, 인코포레이티드 | Parp7 저해제 |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20260098049A1 (en) | 2024-08-12 | 2026-04-09 | Gilead Sciences, Inc. | Kras modulating compounds |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6355010B1 (en) | 1999-03-31 | 2002-03-12 | Coaxia, Inc. | Intravascular spinal perfusion and cooling for use during aortic surgery |
| EP1627869B1 (en) | 2003-05-20 | 2012-05-02 | Ajinomoto Co., Inc. | Vanilloid receptor modulators |
| US20050239921A1 (en) | 2004-04-27 | 2005-10-27 | Birmingham John N | Preparation of organic additive-treated, pyrogenic silica-encapsulated titanium dioxide particles |
| EP1831194A4 (en) * | 2004-12-21 | 2009-12-02 | Astrazeneca Ab | HETEROCYCLIC ANTAGONISTS OF MCHr1 AND THERAPEUTIC APPLICATIONS THEREOF |
| WO2008131047A2 (en) * | 2007-04-16 | 2008-10-30 | The Regents Of The University Of Michigan | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism |
| UY32470A (es) | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
| WO2011048004A1 (en) * | 2009-10-23 | 2011-04-28 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin e2 synthase-1 |
| WO2013146970A1 (ja) * | 2012-03-29 | 2013-10-03 | 第一三共株式会社 | 新規キノリン誘導体 |
| CA2916101A1 (en) | 2013-06-20 | 2014-12-24 | Novasaid Ab | Piperidinyl benzoimidazole derivatives as mpge-1 inhibitors |
| JO3581B1 (ar) | 2014-10-29 | 2020-07-05 | Lilly Co Eli | مركبات ميثيل-بيبيريدين جديدة مفيدة لتثبيط إنزيم سينثاز -1 بروستاجلاندين e2 ميكروسومي |
-
2015
- 2015-10-19 TW TW104134251A patent/TW201627299A/zh unknown
- 2015-10-19 AR ARP150103381A patent/AR102361A1/es unknown
- 2015-10-22 EA EA201790764A patent/EA031504B1/ru not_active IP Right Cessation
- 2015-10-22 WO PCT/US2015/056955 patent/WO2016069374A1/en not_active Ceased
- 2015-10-22 MX MX2017005668A patent/MX376894B/es active IP Right Grant
- 2015-10-22 ES ES15787859T patent/ES2744211T3/es active Active
- 2015-10-22 BR BR112017006809-5A patent/BR112017006809B1/pt active IP Right Grant
- 2015-10-22 AU AU2015339737A patent/AU2015339737B2/en active Active
- 2015-10-22 EP EP15787859.6A patent/EP3221304B1/en active Active
- 2015-10-22 NZ NZ730730A patent/NZ730730A/en unknown
- 2015-10-22 KR KR1020177011302A patent/KR101903304B1/ko active Active
- 2015-10-22 JP JP2017522854A patent/JP6425809B2/ja active Active
- 2015-10-22 US US15/520,078 patent/US9969714B2/en active Active
- 2015-10-22 CN CN201580058924.XA patent/CN107001319B/zh active Active
- 2015-10-22 CA CA2963318A patent/CA2963318C/en active Active
-
2017
- 2017-04-27 CL CL2017001050A patent/CL2017001050A1/es unknown
-
2018
- 2018-05-08 US US15/974,076 patent/US20180251446A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3221304B1 (en) | 2019-07-24 |
| KR20170063828A (ko) | 2017-06-08 |
| BR112017006809B1 (pt) | 2023-02-23 |
| EA201790764A1 (ru) | 2017-08-31 |
| CA2963318A1 (en) | 2016-05-06 |
| MX376894B (es) | 2025-03-07 |
| WO2016069374A1 (en) | 2016-05-06 |
| CL2017001050A1 (es) | 2018-01-12 |
| AU2015339737A1 (en) | 2017-04-20 |
| JP2018500280A (ja) | 2018-01-11 |
| AU2015339737B2 (en) | 2018-03-15 |
| EP3221304A1 (en) | 2017-09-27 |
| AR102361A1 (es) | 2017-02-22 |
| US20180251446A1 (en) | 2018-09-06 |
| US9969714B2 (en) | 2018-05-15 |
| NZ730730A (en) | 2018-08-31 |
| KR101903304B1 (ko) | 2018-10-01 |
| BR112017006809A2 (pt) | 2017-12-26 |
| ES2744211T3 (es) | 2020-02-24 |
| CN107001319A (zh) | 2017-08-01 |
| JP6425809B2 (ja) | 2018-11-21 |
| CA2963318C (en) | 2019-06-25 |
| CN107001319B (zh) | 2019-10-01 |
| EA031504B1 (ru) | 2019-01-31 |
| TW201627299A (zh) | 2016-08-01 |
| US20170313679A1 (en) | 2017-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017005668A (es) | Nuevos compuestos de acido carboxilico utiles para inhibir la sintasa-1 de prostaglandina microsomal e2. | |
| AR134022A2 (es) | Nuevos compuestos de metil-piperidina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 | |
| MX2020011449A (es) | Oxiesteroles y metodos de uso de los mismos. | |
| MX2022012313A (es) | Oxisteroles y metodos de uso de los mismos. | |
| UY37900A (es) | Nuevos derivados de rapamicina | |
| MX375970B (es) | Compuestos de triazolopirimidina y usos de los mismos. | |
| MX2018000280A (es) | Oxiesteroles y metodos de uso de los mismos. | |
| MX2017000926A (es) | Acidos carboxilicos heterociclicos como activadores de guanilato ciclasa soluble. | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| MX2016013689A (es) | Compuestos 4-amino-imidazoquinolina. | |
| BR112018003812A2 (pt) | compostos de heteroarila como inibidores de irak e usos dos mesmos | |
| CR20140413A (es) | Inhibidores de serina/treonina cinasa | |
| MX388170B (es) | Polimorfos de selinexor | |
| DOP2017000034A (es) | Compuestos de imidazopiridazina | |
| CO2019001181A2 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
| UY36228A (es) | Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen | |
| UY36110A (es) | Inhibidores de quinasa relacionados con tropomiosina | |
| CO2017009989A2 (es) | Piridopirimidinonas y utilización de las mismas como moduladores de receptores de nmda | |
| DOP2019000021A (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
| EA201892188A1 (ru) | Соединения пирролотриазина в качестве ингибиторов tam | |
| BR112018003343A2 (pt) | compostos heteroarila como inibidores de irak e usos dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |